Open Access Research article

Menin and p53 have non-synergistic effects on tumorigenesis in mice

Kelly A Loffler1*, Arne W Mould13, Paul M Waring2, Nicholas K Hayward1 and Graham F Kay1

Author affiliations

1 Queensland Institute of Medical Research, 300 Herston Road, Herston, QLD, 4006, Australia

2 Department of Pathology, University of Melbourne, Parkville, VIC, 3010, Australia

3 Present address: William Dunn School of Pathology, University of Oxford, Oxford, UK

For all author emails, please log on.

Citation and License

BMC Cancer 2012, 12:252  doi:10.1186/1471-2407-12-252

Published: 18 June 2012



While it is now more than a decade since the first description of the gene mutation underlying the tumour predisposition syndrome multiple endocrine neoplasia type 1 (MEN1), the mechanism by which its protein product menin acts to prevent development of tumours is still poorly understood.


We undertook a genetic experiment to assess whether menin synergises with p53. Mice carrying various combinations of Men1 and Trp53 mutations were generated then survival and pathology assessed.


While homozygous loss of Trp53 in mice resulted in early onset, aggressive tumours and profoundly reduced lifespan, heterozygous loss of either Trp53 or Men1 caused later onset disease, with a spectrum of tumours characteristic of each tumour suppressor gene. Loss of one copy of Men1 in animals also lacking both alleles of Trp53 did not exacerbate phenotype, based on survival, animal weight or sites of pathology, compared to Trp53 deletion alone. Dual heterozygous deletion of Men1 and Trp53 resulted in a small reduction in lifespan compared to the individual mutations, without new tumour sites. In the adrenal, we observed development of cortical tumours in dual heterozygous animals, as we have previously seen in Men1+/− animals, and there was loss of heterozygosity at the Men1 allele in these tumours. Median number of pathology observations per animal was increased in dual heterozygous animals compared with heterozygous loss of Trp53 alone.


Simultaneous heterozygous deletion of Men1 in animals with either heterozygous or homozygous deletion of Trp53 did not result in formation of tumours at any new sites, implying additive rather than synergistic effects of these pathways. Mice that were Men1+/− in addition to Trp53+/− had tumours in endocrine as well as other sites, implying that increase in total tumour burden, at sites typically associated with either Men1 or Trp53 loss, contributed to the slight decrease in survival in Men1+/−: Trp53+/− animals in comparison with their littermates.